Cardiogenic shock (CS) is a medical emergency resulting from inadequate blood flow due to the dysfunction of the ventricles of the heart. Signs of inadequate blood flow include low urine production (<30 mL/hour), cool arms and legs, and altered level of consciousness. People may also have a severely low blood pressure and heart rate.
Causes of cardiogenic shock include cardiomyopathic, arrhythmic, and mechanical. CS is most commonly precipitated by acute myocardial infarction. Cardiogenic shock is a type of circulatory shock, there is insufficient blood flow and oxygen supply for biological tissues to meet the metabolic demands for oxygen and nutrients. Cardiogenic shock is defined by sustained low blood pressure with tissue hypoperfusion despite adequate left ventricular filling pressure. People can have combined types of shock. Shock by definition is inadequate blood circulation to the rest of the body, which causes organ damage. Organs do not have enough oxygen delivery, and cannot adequately maintain their cellular metabolism.
Mortality rates have been decreasing in the United States. This is likely due to the rapid identification and treatment of the CS. Some studies have suggested that this possibly related to the increased use of coronary reperfusion strategies, like heart stents. Nonetheless, the mortality rates remain high. Multi-organ failure is associated with higher rates of mortality.
myocardial infarction (ST-elevation MI, STEMI, is usually more dangerous than non-STEMIs; MIs that affect the ventricles are usually more dangerous than those that affect the atria; those affecting the left side of the heart, especially the left ventricle, are usually more dangerous than those affecting the right side, unless that side is severely compromised)
When cardiomyopathy is suspected as the cause of cardiogenic shock, a biopsy of heart muscle may be needed to make a definite diagnosis.
If the cardiac index falls acutely below 2.2 L/min/m2, the person may be in cardiogenic shock.
Depending on the type of cardiogenic shock, treatment involves infusion of fluids, or in shock refractory to fluids, inotropic medications. In case of an abnormal heart rhythm several anti-arrhythmic agents may be administered, e.g. adenosine.
Positive inotropic agents (such as dobutamine or milrinone), which enhance the heart's pumping capabilities, are used to improve the contractility and correct the low blood pressure. Should that not suffice an intra-aortic balloon pump (which reduces workload for the heart, and improves perfusion of the coronary arteries) or a left ventricular assist device (which augments the pump-function of the heart) can be considered. Finally, as a last resort, if the person is stable enough and otherwise qualifies, heart transplantation, or if not eligible an artificial heart, can be placed. These invasive measures are important tools—more than 50% of patients who do not die immediately due to cardiac arrest from a lethal abnormal heart rhythm and live to reach the hospital (who have usually suffered a severe acute myocardial infarction, which in itself still has a relatively high mortality rate), die within the first 24 hours. The mortality rate for those still living at time of admission who suffer complications (among others, cardiac arrest or further abnormal heart rhythms, heart failure, cardiac tamponade, a ruptured or dissecting aneurysm, or another heart attack) from cardiogenic shock is even worse around 85%, especially without drastic measures such as ventricular assist devices or transplantation.
Cardiogenic shock may be treated with intravenous dobutamine, which acts on β1 receptors of the heart leading to increased contractility and heart rate.
^Kataja, Anu; Tarvasmäki, Tuukka; Lassus, Johan; Cardoso, Jose; Mebazaa, Alexandre; Køber, Lars; Sionis, Alessandro; Spinar, Jindrich; Carubelli, Valentina; Banaszewski, Marek; Marino, Rossella; Parissis, John; Nieminen, Markku S.; Harjola, Veli-Pekka (2017). "The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock – Results from the Card Shock Study". International Journal of Cardiology. 226: 48–52. doi:10.1016/j.ijcard.2016.10.033. hdl:10138/231345. PMID27788389.
^Basir, Mir B.; Schreiber, Theodore L.; Grines, Cindy L.; Dixon, Simon R.; Moses, Jeffrey W.; Maini, Brijeshwar S.; Khandelwal, Akshay K.; Ohman, E. Magnus; O'Neill, William W. (2017). "Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock". The American Journal of Cardiology. 119 (6): 845–851. doi:10.1016/j.amjcard.2016.11.037. PMID28040188.
^Bagate, François; Lellouche, Nicolas; Lim, Pascal; Moutereau, Stephane; Razazi, Keyvan; Carteaux, Guillaume; De Prost, Nicolas; Dubois-Randé, Jean-Luc; Brun-Buisson, Christian; Mekontso Dessap, Armand (2017). "Prognostic Value of Relative Adrenal Insufficiency During Cardiogenic Shock". SHOCK. 47 (1): 86–92. doi:10.1097/SHK.0000000000000710. PMID27984534.
^Vergara, Ruben; Valenti, Renato; Migliorini, Angela; Cerisano, Giampaolo; Carrabba, Nazario; Giurlani, Letizia; Antoniucci, David (2017). "A New Risk Score to Predict Long-Term Cardiac Mortality in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock and Treated with Primary Percutaneous Intervention". The American Journal of Cardiology. 119 (3): 351–354. doi:10.1016/j.amjcard.2016.10.034. PMID27884422.